Journal
IMMUNOLOGY LETTERS
Volume 168, Issue 2, Pages 319-324Publisher
ELSEVIER
DOI: 10.1016/j.imlet.2015.10.011
Keywords
NF-kappa B; IKK beta inhibitor; Bone marrow-derived macrophages; LPS; Inflammatory cytokines
Categories
Funding
- UNMC-Buffett Cancer Center
- National Institutes of Health [CA182820]
- Fred and Pamela Buffett Cancer Center Support Grant [P30CA036727]
Ask authors/readers for more resources
Activation of the NF-kappa B pathway is causally linked to initiation and progression of diverse cancers. Therefore, IKK beta, the key regulatory kinase of the canonical NF-kappa B pathway, should be a logical target for cancer treatment. However, existing IKK beta inhibitors are known to induce paradoxical immune activation, which limits their clinical usefulness. Recently, we identified a quinoxaline urea analog 13-197 as a novel IKK beta inhibitor that delays tumor growth without significant adverse effects in xenograft tumor models. In the present study, we found that 13-197 had little effect on LPS-induced NF-kappa B target gene induction by primary mouse macrophages while maintaining considerable anti-proliferative activities. These characteristics may explain absence of inflammatory side effects in animals treated with 13-197. Our data also demonstrate that the inflammation and proliferation-related functions of IKK beta can be uncoupled, and highlight the utility of 13-197 to dissect these downstream pathways. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available